ArticleMolecular biology reports2025
miR-101-3p overexpression suppresses NSCLC progression through Immune-Related gene CALCRL regulation and lncRNA NEAT1 axis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionNon-Small Cell Lung Cancer (NSCLC), a predominant subtype of lung cancer, remains a major cause of cancer-related mortality worldwide and continues to present significant clinical challenges. While microRNAs (miRNAs) are established regulators of cellular pathways, their specific involvement in modulating immunometabolic processes in NSCLC remains underexplored. This study aimed to uncover novel regulatory mechanisms in lung adenocarcinoma (LUAD) through an integrative approach combining computational and experimental strategies, with particular emphasis on miRNA, mRNA, and long non-coding RNA (lncRNA) interactions.
methodsBy analyzing RNA-Seq datasets, we identified differentially expressed miRNAs, genes, and immune-associated transcripts specific to LUAD. Subsequent enrichment and network analyses highlighted key molecular players involved in immune dysregulation and cancer progression. A competing endogenous RNA (ceRNA) network involving miR-101-3p, the gene CALCRL, and lncRNA NEAT1 were constructed to elucidate regulatory hierarchies. Experimental validation included qRT-PCR, Western blot, and luciferase reporter assays to confirm miRNA-mRNA-lncRNA interactions. Functional assays were conducted to assess cancer cell proliferation, oxidative stress, mitochondrial integrity, and apoptosis.
resultsAnalysis revealed significant downregulation of miR-101-3p and concurrent upregulation of CALCRL and NEAT1 in LUAD cell lines. Experimental assays confirmed that miR-101-3p directly targets and negatively regulates CALCRL, while NEAT1 enhances CALCRL expression by competitively binding miR-101-3p. Restoration by doing overexpression of miR-101-3p led to reduced cancer cell growth, increased oxidative stress, disrupted mitochondrial function, decreased ATP levels, and increased apoptotic cell death.
conclusionThe study identifies the miR-101-3p/NEAT1/CALCRL regulatory axis as a key mediator of immunometabolic remodeling in LUAD. These findings underscore the potential of targeting this axis for miRNA-guided therapeutic interventions, presenting a novel strategy to counteract tumor progression in NSCLC.
Indexed as
Identifiers
40974392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.